Literature DB >> 16556543

Synthesis and in vitro properties of dexamethasone 21-sulfate sodium as a colon-specific prodrug of dexamethasone.

In Ho Kim1, Hye Sik Kong, Bo Im Choi, Young Soo Kim, Hee Jung Kim, Young Wook Yang, Yun Jin Jung, Young Mi Kim.   

Abstract

We synthesized dexamethasone 21-sulfate sodium (DS) as a colon-specific prodrug of dexamethasone and investigated its properties. Introduction of a sulfate group to dexamethasone lowered the apparent partition coefficient from 52.5 to 0.27 in 1-octanol/pH 6.8 phosphate buffer at 37 degrees C. DS was stable on incubation with buffer solutions of varied pH or with the upper intestinal contents of rats at 37 degrees C for 24 h. On incubation with the cecal contents, DS was hydrolyzed by producing dexamethasone over 80% of the dose at 10 h. When DS was incubated with the cecal contents collected from trinitrobenzenesulfonic acid (TNBS)-induced colitic rats, the degree of prodrug hydrolysis and production of dexamethasone amounted to 70% of healthy rats. In comparison with prednisolone, hydrocortisone, and cortisone, dexamethasone was stable against bioinactivation by the cecal contents, a desirable property for the development of a colon-specific prodrug. These results demonstrated that DS might be delivered specifically to the colon as an intact form to produce dexamethasone in high yield, suggesting DS as a potential colon-specific prodrug of dexamethasone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556543     DOI: 10.1080/03639040500519441

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  2 in total

1.  Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine.

Authors:  Inho Kim; Hyesik Kong; Younghyun Lee; Sungchae Hong; Jungoh Han; Sunhwa Jung; Yunjin Jung; Young Mi Kim
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

2.  Gut microbiota-driven drug metabolism in inflammatory bowel disease.

Authors:  Femke Crouwel; Hans J C Buiter; Nanne K de Boer
Journal:  J Crohns Colitis       Date:  2020-07-11       Impact factor: 9.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.